Biotech

All Articles

AN 2 one-halfs census, quits phase 3 test after data dissatisfy

.AN2 Rehabs is rethinking its own service in feedback to lackluster midphase information, vowing to ...

Merck spends $700M for bispecific, snooping autoimmune position and also chance to challenge Amgen in cancer

.Merck &amp Co. is actually paying $700 million beforehand to challenge Amgen in a blood stream canc...

Gilead spends J&ampJ $320M to exit licensing package for seladelpar

.Along With Gilead Sciences about to an FDA decision for its own liver disease medication seladelpar...

' All hands on deck' at Lilly as peers target weight problems market

.CEO David Ricks can easily observe the firms putting together outdoors tents at basecamp behind Eli...

Entero giving up workers, vacating workplace and also pausing R&ampD

.Cushion Liquidators has actually transformed Entero Rehabs white colored as a slab. The financial i...

Exelixis falls ADC after deciding it's no suit for Tivdak

.Exelixis is losing hope on its own cells variable (TF)- targeting antibody-drug conjugate after con...

Relay loses interest in SHP2 inhibitor after Genentech leaves behind

.3 weeks after Roche's Genentech unit ignored an SHP2 inhibitor contract, Relay Rehab has validated ...

Stoke's Dravet syndrome med discharged of predisposed clinical grip

.Stoke Therapeutics' Dravet disorder medication has actually been actually devoid of a partial grip,...

Fierce Biotech's Gabrielle Masson offers Strong 15 at NYSE

.Ferocious Biotech Associate Editor Gabrielle Masson offered the 2024 course of Brutal 15 champions ...

Daiichi spends Merck $170M to create bronchi cancer T-cell engager pact

.Merck &amp Co. has actually promptly redeemed some of the prices of its own Weapon Rehabs acquistio...